NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

TORONTO, Ontario and HAIFA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system (“CNS”) injuries is pleased to provide a business update and reported financial results for the fourth quarter and financial year ended December 31, 2025. The Company’s lead program, ExoPTEN, is being developed for acute spinal cord injury and optic nerve damage, with additional potential indications including traumatic brain injury and facial nerve injury.

The Company’s audited consolidated financial statements for the fiscal years ended December 31, 2025 and 2024 and accompanying management discussion and analysis can be accessed by visiting the Company's website at www.nurexone.com and its SEDAR+ profile at www.sedarplus.ca.

2025 Highlights and Significant Milestones

• Advancement of ExoPTEN Therapy: Throughout 2025, the Company continued to refine its preclinical data and address feedback from the U.S. Food and Drug Administration (“FDA”) as it advanced key milestones towards the submission of an Investigational New Drug (“IND”) application for ExoPTEN. NurExone generated additional encouraging preclinical results that strengthened confidence in ExoPTEN’s therapeutic potential, while also advancing work on dosing, manufacturing, and product characterization. These efforts support preparation for regulatory review, clinical development and first-in-human clinical trials.
  
  
• Establishment of Exo-Top and U.S. Expansion: On February 4, 2025, the Company established Exo-Top Inc., (“Exo-Top”) a wholly owned U.S. subsidiary in Nevada. This strategic move, together with the acquisition of a proprietary Master Cell Bank (“MCB”), supports the independent production and commercial supply of high-quality naïve exosomes for the Company’s future pipeline.
  
  
• Financial Strengthening: During the year ended December 31, 2025, the Company significantly strengthened its capital structure and liquidity position through a series of private placements, warrant exercises, and stock option exercises, generating aggregate gross proceeds of approximately US$5.9 million. These financing activities supported the Company’s ongoing operations and development initiatives. Key transactions included: